Atherothrombotic disease is a leading public health problem. Although current antiplatelet agents, such as aspirin and adenosine diphosphate (ADP)-receptor antagonists, reduce the morbidity and mortality associated with atherothrombotic disease, the residual risk for ischemic events remains substantial. The high residual risk despite dual antiplatelet therapy can be attributed to the fact that platelets possess multiple pathways of activation that are not all inhibited by aspirin and ADP-receptor antagonists. Among these, binding of thrombin to the proteinase-activated receptor 1 (PAR 1 ) is the most potent platelet activation pathway. In addition, the PAR 1 pathway does not appear to be essential for initiating hemostasis. Inhibition of the PAR 1 receptor thus offers a possible new therapeutic approach with a potentially improved benefit-torisk profile for treatment of patients with atherothrombotic disease. Preclinical and clinical studies have confirmed that SCH 530348, a potent, orally active thrombin-receptor antagonist selective for PAR 1 , does not increase bleeding liability when added to dual antiplatelet therapy. Currently, two large ongoing phase 3 clinical trials are evaluating the efficacy and safety of SCH 530348 in combination with the standard of care in patients with acute coronary syndromes as well as for secondary prevention in patients with previous history of atherothrombotic disease.
Pathophysiology of atherothrombotic disease
Atherothrombotic disease is the leading cause of death worldwide (1) . Acute manifestations of atherothrombotic disease, including acute coronary syndromes, ischemic stroke/ transient ischemic attack, and symptomatic peripheral artery disease, result from inadequate blood supply caused by thrombotic occlusion of the arteries in response to either the rupture of atherosclerotic lesions or the erosion of endothelial cells (2) . Platelets play a critical role in the formation of an arterial thrombus, as well as in normal hemostasis (3) . Normal hemostasis ("good clotting") occurs in response to injury and involves platelet adhesion to the vessel wall (mediated by von Willebrand factor and collagen), activation and recruitment of additional platelets (mediated primarily by collagen-stimulated release of thromboxane A 2 and adenosine 5'-diphosphate [ADP] from adherent platelets) to form a hemostatic plug (3) , and stabilization of the hemostatic plug by fibrin mesh generated from fibrinogen through the enzymatic activity of thrombin. In pathologic atherothrombosis ("bad clotting"), rupture of atherosclerotic lesions or erosion of endothelial cells is followed by uncontrolled platelet activation by multiple agonists, such as thrombin, thromboxane A 2 , ADP, and others, leading to extensive platelet aggregation (mediated by the platelet glycoprotein [GP] IIb / IIIa receptor) that ultimately results in thrombotic occlusion of blood flow (3).
The central role of platelet activation in the pathophysiology of atherothrombotic disease is supported by the well-documented benefits of long-term antiplatelet therapy with aspirin and clopidogrel (3) . However, the residual morbidity and mortality of patients with atherothrombotic disease remain high despite dual antiplatelet therapy, including therapy with the newer and possibly more potent antiplatelet agents (e.g., the P2Y 12 ADP-receptor antagonist prasugrel) (4 -6) . In addition, both aspirin and P2Y 12 ADP-receptor antagonists (clopidogrel and prasugrel) have been associated with increased bleeding, including fatal bleeding (4 -6) . These considerations underscore the need for antiplatelet agents with a novel mechanism of action that can provide further reductions in morbidity and mortality, preferably without exacerbating the bleeding risk associated with current therapeutic approaches.
Platelet activation pathways and targets of oral antiplatelet drugs
Multiple pathways are involved in the activation of platelets, a critical step in platelet-mediated thrombosis (3, 7) . Platelet activation is initiated and perpetuated by binding of multiple agonists (such as thrombin, ADP, thromboxane A 2 , collagen, serotonin, epinephrine, and others) to specific G-protein-coupled receptors on platelets (3, 7) , and these pathways are generally independent of each other ( Fig. 1) (8) . Proteinase-activated receptor 1 (PAR 1 ) is the platelet receptor for thrombin, the most potent platelet agonist. A second platelet receptor for thrombin, PAR 4 , may provide some redundancy (3), as it becomes activated only at higher thrombin concentrations (7) . P2Y 1 and P2Y 12 receptors mediate platelet activation by ADP (3, 7) . TPα and TPβ receptors mediate platelet activation by thromboxane A 2 (3, 7) .
Current oral antiplatelet agents inhibit the platelet synthesis of thromboxane A 2 (aspirin) or P2Y 12 ADP receptor-mediated platelet activation (ticlopidine and clopidogrel; new agents in this class include prasugrel and ticagrelor [AZD 6140]; cangrelor is a novel intravenous P2Y 12 ADP-receptor antagonist) (3, 9) . However, neither aspirin nor P2Y 12 ADP-receptor antagonists have a direct inhibitory effect on thrombinmediated platelet activation via the PAR 1 -receptor pathway. Because thrombin is the most potent platelet activator, inhibition of the PAR 1 receptor offers a rational approach to the development of novel antiplatelet agents that can potentially address the ischemic risk that remains in patients despite therapy with aspirin and an ADP-receptor antagonist (3, 9) .
A thrombin-receptor antagonist (TRA) selective for PAR 1 , used in combination with aspirin and an ADPreceptor antagonist, can provide more comprehensive inhibition of platelet activation than aspirin and an ADPreceptor antagonist alone, thereby potentially reducing the risk of thrombosis and acute ischemic events. Additionally, because the PAR 1 receptor may not be essential for normal hemostasis, as suggested by several studies (10 -14) , its inhibition may not be associated with increased bleeding risk. von Willebrand factor and the collagen receptors GPVI and GPIa are essential in initiating platelet adhesion to the site of vascular injury during the formation of a hemostatic plug, which is then stabilized by thrombin-mediated fibrin formation. Aspirin and ADP-receptor antagonists attenuate / inhibit collagen-induced platelet aggregation, suggesting that these agents might interfere with thrombosis and normal hemostasis. Aspirin and ADP-receptor antagonists have therefore been associated with increased bleeding risk (3). Importantly, PAR 1 antagonists also do not interfere with the procoagulant activity of thrombin. However, direct thrombin inhibitors (bivalirudin, hirudin, argatroban, and dabigatran) bind directly to thrombin and block its procoagulant activity (15) . While the binding of direct thrombin inhibitors to thrombin makes less thrombin unavailable for the activation of PAR 1 on platelets, these agents do not directly affect PAR 1 activity. Therefore, it remains unclear if the physiologic concentrations of direct thrombin inhibitors achieved with the current dosing regimens of these agents can yield clinically relevant levels of inhibition of the thrombin -PAR 1 platelet activation pathway. In this context, it is important to stress that thrombin is the most potent platelet activator; only sub-nanomolar concentrations of thrombin are necessary to activate platelets via the PAR 1 receptor (16, 17) .
TRAs selective for PAR 1 : identification of lead compounds
Thrombin activates human platelets via PAR 1 by binding to the extracellular loop of the receptor, which is then cleaved to form a new amino terminus with its tethered ligand; the tethered ligand activates the autoreceptor ( Fig. 2) (18, 19) . Synthetic peptides, called thrombin-receptor agonist peptides (TRAPs), that mimic the new amino terminus potently activate the thrombin receptor and can cause platelet activation, secretion, and aggregation independently of receptor cleavage. Commercially available TRAPs have low affinities for PAR 1 ; thus, more potent TRAPs were synthesized, and a high-throughput thrombin receptor-binding assay with human platelet membranes was subsequently used to screen and identify initial lead(s) selective for PAR 1 (20, 21) . A series of potent and selective compounds with high affinity for PAR 1 were identified using this assay. Secondary functional assays (e.g., washed human platelet aggregation assay with TRAP and thrombin as agonists, TRAP-stimulated calcium transients in human coronary smooth muscle cells [HCSMC], and thrombinstimulated thymidine incorporation into HCSMC [a surrogate for cellular proliferation in response to injury]) (20) were subsequently used to profile the lead compounds for further study. Together, these assays corroborated that the lead compounds were antagonists of PAR 1 that inhibited thrombin-and TRAP-mediated, PAR 1 -dependent events but had no effect on the enzymatic activity of thrombin.
Efficacy of PAR 1 antagonism in animal models of thrombosis
Standard species used in preclinical research, such as mice, rats, rabbits, and dogs, do not express PAR 1 on their platelets and are thus not suitable for evaluation of PAR 1 antagonists (22) . In contrast, nonhuman primates (including cynomolgus monkeys, rhesus monkeys, and baboons) express PAR 1 on their platelets (23) . With the goal of developing orally active drugs, an ex vivo model of platelet aggregation was established in chairtrained, conscious cynomolgus monkeys. Initial studies demonstrated that lead compounds effectively inhibited TRAP-induced ex vivo platelet aggregation in assays using whole blood (23) . Lead compounds were subsequently evaluated in various models of thrombosis.
SCH 205831, a potent, selective, and orally active PAR 1 antagonist, significantly inhibited thrombosis in an arteriovenous-shunt model in conscious baboons (24) . SCH 602539, another potent, selective, and orally active PAR 1 antagonist (formulated for intravenous administration), inhibited thrombosis in a dose-dependent manner in the Folts model of thrombosis in anesthetized cynomolgus monkeys (25) . In the same study, an antithrombotic effect was also demonstrated with an intravenous ADP-receptor antagonist, cangrelor, and, when coadministered, the 2 compounds targeting different platelet activation pathways exhibited additive (and potentially synergistic) antithrombotic effects (25) . These data are consistent with the antithrombotic effect previously demonstrated with the antibody to PAR 1 as well as peptide and nonpeptide PAR 1 antagonists in animal models (10, 12, 13) , suggesting that PAR 1 antagonists may be a valuable treatment approach in atherothrombotic disease.
The potency and pharmacokinetic profiles of the lead compounds were further optimized, resulting in the discovery of SCH 530348, a novel, orally active TRA selective for PAR 1 with potent antiplatelet activity, which was selected for further development (26) . A recent study demonstrated that oral administration of SCH 530348 at doses ≥0.1 mg / kg provided 100% inhibition of ex vivo platelet aggregation for 24 h in platelets from cynomolgus monkeys (26) . In human platelet-rich plasma, SCH 530348 inhibited thrombininduced and TRAP-induced platelet aggregation with 50% inhibitory concentration (IC 50 ) values of 47 and 25 nM, respectively, without affecting the aggregation induced by ADP, thromboxane A 2 mimetic U46619, or collagen (26) . Importantly, SCH 530348 did not affect coagulation parameters (prothrombin time and activated partial thromboplastin time), suggesting that the potential for bleeding events may not be increased (26) . SCH 530348 also demonstrated excellent bioavailability (86% in monkeys) (26) .
Consistent with the pharmacologic profile of SCH 530348, treatment of cynomolgus monkeys with SCH 530348, either alone or in combination with aspirin plus clopidogrel, did not increase surgical blood loss or bleeding times versus placebo and aspirin plus clopidogrel, respectively (27) . Additionally, SCH 530348 did not affect coagulation parameters (as measured by activated clotting time) and selectively inhibited TRAPinduced platelet aggregation, without affecting aggregation induced by ADP, thromboxane A 2 mimetic U46619, or collagen (27) .
Clinical development of SCH 530348, a novel PAR 1 antagonist
On the basis of positive results in animal models of thrombosis, SCH 530348 was advanced into clinical development. A phase 1 study in healthy human subjects demonstrated that SCH 530348 is safe and well tolerated (28) . Single oral doses of SCH 530348 (5 to 40 mg) produced >90% mean inhibition of TRAP-induced platelet aggregation across all subjects for >72 h (28) . In a separate, recently reported phase 1 study in healthy subjects, the dosing regimen of SCH 530348 that most consistently provided the targeted level of TRAPinduced platelet aggregation inhibition throughout the entire 28-day treatment period was a 40-mg loading dose followed by a 2.5-mg once-daily maintenance dose (29) .
SCH 530348 was also evaluated in a double-blind, placebo-controlled, dose-ranging phase 2 clinical trial in patients scheduled for nonemergent percutaneous coronary intervention (PCI) (the Thrombin Receptor Antagonist for Cardiovascular Event Reduction in Percutaneous Coronary Interventions [TRA-PCI] study), conducted at 76 international centers. The primary objective of the TRA-PCI study was to evaluate the safety and tolerability of SCH 530348 (30) . The TRA-PCI study randomized 1,030 patients in a 3:1 ratio to loading doses of 10, 20, or 40 mg SCH 530348 or placebo (30) . The primary evaluable cohort included 573 patients who underwent nonemergent PCI (the vast majority of whom received aspirin and clopidogrel, as well as an anticoagulant) and were randomized to oncedaily maintenance dosing (0.5, 1, or 2.5 mg, depending on the loading dose) for 60 days. The remaining 457 patients did not undergo PCI. The addition of SCH 530348 to standard antiplatelet therapy (aspirin plus clopidogrel) was not associated with increases in Thrombolysis in Myocardial Infarction (TIMI) major plus TIMI minor bleeding, as compared with the placebo group (Table 1) (30) . Although the study was not sufficiently powered to evaluate efficacy, there was a strong trend toward numerical reductions in death and major adverse cardiac events, including myocardial infarction (MI) in the SCH 530348-treated group compared with the placebo-treated group. These numerical reductions in events were evident with all doses of SCH 530348, with a trend toward lower rates with the higher loading doses (Table 1 ) (30) . A 40-mg loading dose of SCH 530348 achieved >80% inhibition of TRAP-induced platelet aggregation in 1 -2 h in the vast majority of subjects, and the 2.5 mg maintenance dose led to sustained >80% inhibition of platelet aggregation (31) . Two additional phase 2 studies conducted in Japanese patients (one in patients with acute coronary syndromes and one in patients with ischemic stroke) have confirmed the favorable safety profile of SCH 530348 observed in the TRA-PCI study (unpublished results). In addition, the study performed in Japanese patients with acute coronary syndromes demonstrated a reduction in periprocedural myocardial infarctions, similar to the findings reported in the TRA-PCI study (32, 33) .
Encouraging data from the TRA-PCI study have led to the initiation of two large phase 3 efficacy and safety trials with SCH 530348, one in patients presenting with non-ST-segment elevation acute coronary syndromes (TRA ⋅ CER, N = 10,000) and the other in the setting of secondary prevention in patients with prior atherothrombotic ischemic events (TRA 2P-TIMI 50, N = 19,500).
Conclusions
Despite the proven benefits and the wide use of dual oral antiplatelet therapy with aspirin and ADP-receptor antagonists, the morbidity and mortality rates of patients with atherothrombotic disease remain high. The residual risk for ischemic events could be attributed to the fact that aspirin and ADP-receptor antagonists each block only one of the multiple platelet activation pathways and do not interfere with the other pathways, including the critical one that involves the activation of PAR 1 by thrombin. Therefore, inhibition of the PAR 1 receptor for thrombin offers a possible approach to the development of novel antiplatelet agents. In preclinical studies, PAR 1 antagonism demonstrated selective inhibition of PAR 1mediated platelet aggregation and thrombosis, an additive antithrombotic effect when coadministered with the ADP-receptor antagonist cangrelor, and lack of increased bleeding risk, when used either alone or in combination with aspirin and clopidogrel. SCH 530348 was safe and well tolerated in the phase 1 and 2 clinical studies. Furthermore, treatment with SCH 530348 was associated with a strong trend toward numerical reduction in the incidence of arterial thrombotic events without an increase in bleeding risk. These data suggest that in patients with atherothrombotic disease, the addition of SCH 530348 to the current standard of antiplatelet therapy may offer incremental reduction in ischemic events without incurring an additional bleeding risk. The efficacy and safety of SCH 530348 are currently being evaluated in two large phase 3 trials.
